Evidence map›Paper›PMID 42603143›Full record

ArticleCancer2026

Analysis of real-world clinical outcomes of perioperative chemotherapy compared to preoperative chemoradiotherapy in esophagogastric adenocarcinoma.

Mosunmoluwa Oyenuga, Subir Goyal, Lindsay M Hannan, Oluwadunni Emiloju, Gideon T Dosunmu, Ruoyu Miao, Olumide Gbolahan, Maria Russell, Jolinta Lin, Jeffrey M Switchenko and 1 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mosunmoluwa OyenugaDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
Subir GoyalBiostatistics Shared Resource, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
Lindsay M HannanDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
Oluwadunni EmilojuDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
Gideon T DosunmuDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
Ruoyu MiaoDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
Olumide GbolahanDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0002-0598-4809
Maria RussellDepartment of Surgery, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
Jolinta LinDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
Jeffrey M SwitchenkoBiostatistics Shared Resource, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0002-5563-9325
Olatunji B AleseDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.

Funding

Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Ragini Reiney Kudchadkar · 2009 to 2026
$47.5M
NCI NIH HHS P30 CA138292
6 · The paper itself

Abstract

backgroundNonmetastatic esophagogastric adenocarcinoma require multimodal treatment for management. However, real-world treatment patterns and outcomes in these patients are limited. We evaluated the survival outcomes associated with the common treatment combinations in the National Cancer Database.

methodsA total of 4715 patients met the predefined inclusion and exclusion criteria. Four groups were created: group 1, preoperative chemotherapy; group 2, perioperative chemotherapy; group 3, preoperative chemotherapy followed by chemoradiation; and group 4, preoperative chemoradiotherapy. Kaplan-Meier curves were used to assess overall survival. Cox proportional hazard regression estimated hazard ratios (HR) and 95% CIs for associations between covariates and overall survival. Inverse probability of treatment weighting based on propensity scores were used to account for differences in baseline characteristics between treatment groups.

resultsThe median age was 63 years; 75.9% were male and 82.9% were non-Hispanic White; overall, 47.5% had clinical stage III disease and 57.8% had regional lymph node involvement. Median follow-up was 79.5 months. Patients who received perioperative chemotherapy had improved median overall survival compared with patients who received preoperative chemoradiotherapy (79.1 vs 74.6 months; p < .001). After adjustment for age, race, Charlson-Deyo Score, facility type, year of diagnosis, presence of regional lymph nodes, clinical stage, the association remained statistically significant (HR = 0.78; 95% CI, 0.66-0.92; p = .003).

conclusionAlthough several multimodality treatment strategies are used for esophagogastric adenocarcinoma, perioperative chemotherapy is associated with better overall survival compared to preoperative chemoradiotherapy.

Indexed as

AdenocarcinomaChemoradiotherapyEsophageal NeoplasmsStomach NeoplasmsAgedChemotherapy, AdjuvantEsophagogastric JunctionFemaleHumansKaplan-Meier EstimateMaleMiddle AgedNeoadjuvant TherapyNeoplasm StagingPerioperative CareRetrospective Studieschemoradiotherapyesophageal carcinomagastric carcinomagastroesophageal junction tumorsimmunotherapyneoadjuvant therapiesnovel therapeuticssystemic treatment

Identifiers

PMID42603143
PMCPMC13476985

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.